La cadena de opciones muestra datos clave de las opciones de acciones de Guardant Health a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Guardant Health..

Guardant Health (NASDAQ:GH) Bolsa, Cadena de Opciones

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Equities

News

Markets

ETFs

$BTC

ARKF

ARKG

ARKK

ARKW

COIN

EXAS

PLTR

PSNL

VRTX

El miércoles, Cathie Wood, a la cabeza de Ark Invest, realizó algunas operaciones significativas, siendo las más destacadas las de Coinbase Global Inc (NASDAQ:COIN) y Palantir Technologies Inc (NYSE:

Movimientos clave de Cathie Wood: ¿qué hay detrás de las últimas operaciones de Ark Invest?

Guardant Health Inc

HSBC BANK 30/10/26 WNT

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX, Inc. - Class A Common Stock

Gores Holdings IX Inc

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by GREENHEART GOLD INC.

GUARDION HLTH SCIENCS INC by Guardion Health Sciences, Inc.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

AMD GLOB HY ETF

Organon's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) short percent of float has risen 28.4% since its last report. The company recently reported that it has 12.53 million shares sold short, which is 6.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Organon Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731008721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Organon has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Organon's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Organon's peer group average for short interest as a percentage of float is 4.63%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Organon's Recent Short Interest

Nexalin Technology's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NYSE">NXL</a>) short percent of float has risen 30.38% since its last report. The company recently reported that it has 93 thousand shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Nexalin Technology Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731008715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nexalin Technology has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Nexalin Technology's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Nexalin Technology's peer group average for short interest as a percentage of float is 2.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(NXL) - Analyzing Nexalin Technology's Short Interest

WIIM

MEOH

Methanex shares are trading higher after the company reported better-than-expected Q3 revenue results. UBS maintained a Buy rating on the stock.

Credo Technology Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NYSE">CRDO</a>) short percent of float has fallen 6.93% since its last report. The company recently reported that it has 6.94 million shares sold short, which is 4.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Credo Technology Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731008710_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Credo Technology Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Credo Technology Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Credo Technology Group's peer group average for short interest as a percentage of float is 4.51%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CRDO

Peering Into Credo Technology Group's Recent Short Interest

Oppenheimer analyst Ken Wong maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Outperform and raises the price target from $625 to $740.

Price Target

Analyst Ratings

HUBS

Oppenheimer Maintains Outperform on HubSpot, Raises Price Target to $740

<a href="https://www.youtube.com/live/8rQlEH86FCM?si=s1GWbEOy5eqm4Jq5" title="https://www.youtube.com/live/8rQlEH86FCM?si=s1GWbEOy5eqm4Jq5">https://www.youtube.com/live/8rQlEH86FCM?si=s1GWbEOy5eqm4Jq5</a>

Federal Reserve

Fed's Powell Says Not Ruling It Out Or In, When Asked About 2025 Rate Cut Projections From September

PureCycle Technologies shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $95 to $105.

GILD

Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to $105

<a href="https://www.youtube.com/watch?v=8rQlEH86FCM">https://www.youtube.com/watch?v=8rQlEH86FCM</a>
&nbsp;

Macro Economic Events

Econ #s

Economics

Fed Chair Powell Says Asking Ourselves Is That Where We Need To Be; Trying To Steer Between Moving Too Quickly And Moving Too Slowly; Trying To Be On A Middle Path; We Think That's Where We Are But That's The Question We Will Be Asking In December; We Are On Path Toward A More Neutral Stance; Will Have To See Where The Data Leaves Us

LGND

Ligand Pharmaceuticals shares are trading higher after the company reported worse-than-expected Q3 financial results and raised its FY24 guidance.

Needham analyst Ryan Koontz maintains AudioCodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) with a Buy and lowers the price target from $14 to $11.

AUDC

Needham Maintains Buy on AudioCodes, Lowers Price Target to $11

Macro Notification

General

White House Says We Will Keep Surging Aid To Ukraine

Oppenheimer analyst Brian Schwartz maintains Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) with a Outperform and raises the price target from $31 to $35.

CWAN

Oppenheimer Maintains Outperform on Clearwater Analytics Hldg, Raises Price Target to $35

FIVE

Five Below shares are trading higher. Truist Securities raised its price target on the stock from $87 to $88.

<a href="https://www.youtube.com/watch?v=8rQlEH86FCM" title="https://www.youtube.com/watch?v=8rQlEH86FCM">https://www.youtube.com/watch?v=8rQlEH86FCM</a>

Fed Chair Powell Says Since Sept Meeting In The Main Economic Activity Data Has Been Stronger; Overall Take Away A Sense That Downside Risks Of Activity Have Been Diminished; Overall Feeling Good About Economic Activity; Job Report Wasn't Terrible But Was Higher Than Expected; Will Make A Decision On Rates As We Get To December; For December We Will Be Looking At Incoming Data And How That Affects Outlook; In The Process Of Recalibrating From A Fairly Restrictive Level

Northland Capital Markets analyst Ted Jackson downgrades Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) from Outperform to Market Perform and lowers the price target from $30 to $20.

Downgrades

Northland Capital Markets Downgrades Mayville Engineering to Market Perform, Lowers Price Target to $20

Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) investors and fans could have plenty of reasons to smile Thursday with the stock hitting an all-time high and a company update on the beloved show "Stranger Things" and its <a href="https://www.benzinga.com/topic/stranger-things">final season in 2025.</a>
What Happened: Netflix hit "Stranger Things" first premiered on the streaming platform <a href="https://www.benzinga.com/general/entertainment/23/07/33285087/if-you-invested-1-000-in-netflix-stock-when-stranger-things-debuted-heres-how-much-youd-hav">in July 2016 </a>and is set for a fifth and final season. Netflix confirmed this week that the fifth season will be released in 2025, with no planned release date yet.
"We have an incoming transmission from Hawkins, Indiana: Stranger Things Season 5 has started filming. Miss your favorite nerds? They're back, ready (or not) for whatever Vecna has in store for them in the beloved series' final season," Netflix said.
Production began in January and now the company is sharing more details on the upcoming season and providing some behind-the-scenes videos and photos for fans.
Netflix also announced that season 5 will be eight episodes and shared the episode titles, with part of Episode 2 blurred out as a surprise.
<ul>
<li>Episode 1: The Crawl</li>
<li>Episode 2: The Vanishing of …</li>
<li>Episode 3: The Turnbow Trap</li>
<li>Episode 4: Sorcerer</li>
<li>Episode 5: Shock Jock</li>
<li>Episode 6: Escape from Camazotz</li>
<li>Episode 7: The Bridge</li>
<li>Episode 8: The Rightside Up</li>
</ul>
"Stranger Things" creators Matt and Ross Duffer wrote a 25-page mythology document for Netflix back in Season 1 about the lore of the Upside Down. While viewers learned a lot about the Upside Down in Season 4, Netflix said more will be revealed in the final season.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/08/40231770/stranger-things-comes-to-broadway-how-you-can-get-tickets-to-hit-netflix-show-on-stage">Stranger Things Comes To Broadway: How You Can Get Tickets To Hit Netflix Show On Stage</a>
Why It's Important: Stranger Things had eight episodes in its first and third seasons with seasons two and three containing nine episodes each.
Netflix has not confirmed if it will release all the season 5 episodes or split them up. For season 4, "Stranger Things" was split into seven episodes and two episodes across two parts. Each episode was over an hour in length with the season finale episode nine coming in at two hours and 30 minutes and the longest.
The series is one of the most watched in Netflix history and the long gap between season 4 released in 2022 and the fifth season in 2025 could make the final season one of the most anticipated releases in company history.
Netflix <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">ended the third quarter</a> with 282.72 million global paid subscribers and is continuing to bet on original series like "Stranger Things," "Bridgerton" and "Stranger Things to maintain and grow subscribers.
The company is also expanding into live sports and working to grow its ad-supported plans for future revenue growth.
While a second season of "Squid Game" and two NFL games on Christmas Day 2024 make the fourth quarter one of the <a href="https://www.benzinga.com/general/entertainment/24/08/40112559/squid-game-season-2-ignites-august-buzz-with-netflixs-christmas-lineup-including-nfl-games">most anticipated in company history</a>, investors and subscribers could be looking ahead to 2025, which will include a third and final season of "Squid Game," a fifth and final season of "Squid Game" and at least one NFL game.
Price Action: Netflix stock is up 2% to $794.03 on Thursday, hitting an intraday high of $794.20, which is a new all-time high for shares. Netflix stock is up 70% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/07/39824649/stranger-things-creators-have-new-show-coming-to-netflix-what-fans-should-know">&#8216;Stranger Things&#8217; Creators Have New Show Coming To Netflix: What Fans Should Know</a></li>
</ul>
Image: Shutterstock

Entertainment

NFLX

Netflix Stock Hits All-Time Highs, Company Confirms 'Stranger Things' Season 5 For 2025

ABNB

Airbnb shares are trading higher ahead of the company's Q3 earnings report.

DA Davidson analyst Tom White maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Neutral and raises the price target from $11 to $16.

LYFT

DA Davidson Maintains Neutral on Lyft, Raises Price Target to $16

Fed Chair Powell Says Watched Run Up In U.S. Treasury Yields, Nowhere Near Where It Was; Will See Where Bond Rates Settle, Too Early To Say Where; Appears That Moves In Bond Rates Are Not Mostly About Higher Inflation Expectations; Bond Rates Reflecting Growth Expectations; Not At The Stage Where Bond Rates Need To Be Taken Into Policy Consideration; These Things Don't Have Much To Do With Fed Policy

Guardant Health surges 15% on boosted revenue guidance range, Q3 beats

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – AppLovin (APP)&nbsp;up 28.6% ...

Closing Bell Movers: AppLoving up 29% after Q3 earnings beat

Guardant Health, Inc. 2024 Q3 - Results - Earnings Call Presentation

Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript

Guardant Health ( ($GH) ) has released its Q3 earnings. Here is a breakdown of the information Guardant Health presented to its investors. Guardant...

Guardant Health Boosts 2024 Revenue Outlook

TD Cowen analyst Daniel Brennan maintained a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $42.00. Danie...

Guardant Health: Strong Financial Performance and Growth Prospects Lead to Buy Rating

Analyst Mark Massaro of BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), retaining the price target of $50.00. Mark Massaro ...

Guardant Health: Strong Financial Performance and Strategic Growth Potential Earns Buy Rating

Aristotle Large Cap Growth Q3 2024 Commentary

Aristotle Core Equity Q3 2024 Commentary

In a report released today, William Bonello from Craig-Hallum reiterated a Buy rating on Guardant Health (GH – Research Report), with a price targe...

Craig-Hallum Remains a Buy on Guardant Health (GH)

ACLS

ADPT

AMAT

ASPN

BMRN

BROS

CPRX

CTVA

DUOL

DXCM

EXPE

FRSH

GOOG

IDXX

KLAC

MELI

MKSI

MTCH

QCOM

RRGB

RXRX

SEDG

SNPS

SRPT

TNDM

TRIP

TSLA

TTWO

WOLF

Press Releases

Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

Roberto A. Mignone Joins Guardant Health Board of Directors

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024

Guardant Health Named to TIME's List of the Best Inventions of 2024

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Guardant Health

Guardant Health (GH) Opciones

Guardant Health (NASDAQ:GH) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL